

Review - The Role of Convalescent Sera against Coronavirus Diseases

Soumitra Sahana^{1*}, Indrajit Samanta¹, Indranil Chatterjee², Suman Kumar Nath², Rajeswar Das², Snehansu Biswas², Sanchari Chatterjee², Anagh Mukherjee²

¹B. Pharm, Birbhum Pharmacy School, Birbhum, West Bengal, India

²Assistant Professor, Birbhum Pharmacy School, Birbhum, West Bengal, India

*Corresponding Author: Soumitra Sahana, B.Pharm, Birbhum Pharmacy School, Birbhum, West Bengal, India.

Email: sahana2001dipu@gmail.com

Abstract:

In the year of 2020, humanity is opposing a pandemic in severe acute respiratory syndrome coronavirus two. SARS-CoV-2 motives coronavirus disease, abbreviated as COVID-19. At the time of this writing, SARS-CoV-2 is expanding in a couple of countries, frightening a pandemic that will have an effect on billions of people. This virus looks to be a new human pathogen. Currently there are no vaccines, monoclonal antibodies, or pills handy for SARS-CoV-2, even though many are in fast improvement and some might also be reachable in a quick time. This Viewpoint argues that human convalescent serum is an choice for prevention and therapy of COVID-19 sickness that ought to be unexpectedly accessible when there are enough numbers of humans who have convalesced and can contribute immunoglobulin containing serum. Passive antibody remedy Passive antibody remedy includes the administration of antibodies towards a given agent to a inclined person for the motive of stopping or treating an infectious disorder due to that agent. In contrast, energetic vaccination requires the induction of an immune response that takes time to improve and varies relying on the vaccine recipient. Thus, passive antibody administration is the solely skill of supplying on the spot immunity to inclined persons. Passive antibody remedy has a storied records going again to the Nineties and was once the solely ability of treating positive infectious illnesses prior to the improvement of antimicrobial remedy in As of early 2020, humanity is confronting a pandemic in extreme acute respiratory syndrome coronavirus two (SARS-CoV-2). SARS-CoV-2 reasons coronavirus disease, abbreviated as COVID-19. At the time of this writing, SARS-CoV-2 is spreading in a couple of countries, threatening a pandemic that will affect billions of people. This virus looks to be a new human pathogen. Currently there are no vaccines, monoclonal antibodies (mAbs), or pills accessible for SARS-CoV-2, though many are in speedy improvement and some may also be handy in a quick time. This Viewpoint argues that human convalescent serum is an alternative for prevention and therapy of COVID-19 disorder that should be hastily on hand when there are enough numbers of humans who have convalesced and can contribute immunoglobulin containing serum.

Passive antibody therapy

Passive antibody remedy includes the administration of antibodies towards a given agent to a inclined character for the cause of stopping or treating an infectious disorder due to that agent. In contrast, energetic vaccination requires the induction of an immune response that takes time to increase and varies relying on the vaccine recipient. Thus, passive antibody administration is the solely skill of offering instant immunity to inclined persons. Passive antibody remedy has a storied records going returned to the Eighteen Nineties and used to be the solely skill of treating sure infectious ailments prior to the improvement of antimicrobial remedy in the Nineteen Forties (1, 2). Occurrence from prior outbreaks with different coronaviruses, including SARS-CoV-1, suggests that such convalescent sera include counteracting antibodies to the applicable virus(3).In the case of SARS-CoV-2, the expected mechanism of motion via which passive antibody remedy would mediate safety is viral neutralization. However, different mechanisms may additionally be possible, such as antibody-dependent cell cytotoxicity and/or phagocytosis. Possible sources of antibody for SARS-CoV-2 are human convalescent sera from folks who have recovered from COVID-19, mAbs, or preparations generated in positive animal hosts, such as genetically engineered cows that produce human antibody (4). Although many sorts of preparations are or will quickly be below development, the solely antibody kind that is presently on hand for on the spot use is that determined in human convalescent sera (Figure 1). As greater men and women contract COVID-19 and recover, the wide variety of practicable donors will proceed to increase.

A popular precept of passive antibody remedy is that it is extra nice when used for prophylaxis than for cure of disease. When used for therapy, antibody is most nice when administered rapidly after the onset of symptoms. The purpose for temporal version in efficacy is no longer nicely understood however should mirror that passive antibody works with the aid of neutralizing the initial inoculum, which is possibly to be a lot smaller than that of hooked up ailment (5). Another clarification is that antibody works by way of editing the inflammatory response, which is additionally greater effortlessly executed for the duration of the preliminary immune response, a stage that may also be asymptomatic (6). As an example, passive antibody remedy for pneumococcal pneumonia used to be most advantageous when administered rapidly after the onset of symptoms, and there used to be no advantage if antibody administration used to be delayed previous the 0.33 day of disorder (7). For passive antibody remedy to be effective, a enough quantity of anti- physique need to be administered. When given to a inclined person, this antibody will flow into in the blood, attain tissues, and furnish safety in opposition to infection. Depending on the antibody quantity and composition, the safety conferred via the transferred immunoglobulin can final from weeks to months.

Historical precedents

In the early 21 century’s convalescent sera was once used to stem explosion of viral ailments such as poliomyelitis (8), measles (9, 10), mumps (11), and influenza (12). A retrospective meta analysis of 8 research on the use of convalescent sera involving 1703 outpatients for the duration of the 1918 H1N1 influenza virus pandemic cautioned that these who obtained serum had decrease mortality (13). Although the efficacy of convalescent sera diverse with the virus and the study, there was once consensus at the time that this intervention used to be useful, and it used to be severa outbreaks. It is noteworthy that historically, convalescent sera had been developed and used in many instances besides the ability to measure antibody titers or expertise about viral serotypes, and in scientific research that did now not meet cutting-edge standards for randomization or blinding.

More recently, convalescent serum used to be used throughout viral epidemics. In the 2009–2010 H1N1 influenza virus pandemic, convalescent serum antibody preparations acquired via apheresis had been used to deal with persons with extreme H1N1 2009 contamination requiring intensive care (14). Serum-treated humans manifested decreased respiratory viral burden, serum cytokine responses, and mortality (14). Convalescent serum used to be additionally used in the 2013 West African Ebola epidemic. A small nonrandomized learn about in Sierra Leone printed extensively longer survival for these handled with convalescent complete blood relative to these who acquired widespread cure (15). Two sufferers transferred to the United States and handled with a mixture of convalescent serum and an experimental drug additionally survived (16). There is anecdotal proof from the H5N1 (17, 18) and H7N9 (19) avian flu out breaks that use of convalescent sera was once effective, with all sufferers surviving.

Although each and every viral disorder and epidemic is different, these experiences furnish essential historic precedents that are each reassuring and beneficial as humanity now confronts the COVID-19 epidemic.




Figure 1. Schematic of the use of convalescent sera for COVID-19. A character who is ill with COVID-19 and recovers has blood drawn and screened for virus-neutralizing antibodies.

Following identification of these with excessive titers of neutralizing antibody, serum containing these virus-neutralizing anti-our bodies can be administered in a prophylactic manner to forestall contamination in high-risk cases, such as susceptible men and women with underlying scientific conditions, fitness care providers, and persons with publicity to validated instances of COVID-19. Additionally, convalescent serum ought to probably be used in men and women with medical disorder to decrease signs and symptoms and mortality. The efficacy of these procedures is no longer known, however historic ride suggests that convalescent sera can also be extra high-quality in stopping disorder than in the therapy of hooked up sickness.

Experience with the use of convalescent sera against coronavirus diseases

In the 21 century, there have been two different epizootic with coronaviruses that had been related with excessive mortality, SARS-1 in 2003 and Middle East respiratory syndrome in 2012. The SARS1 epidemic used to be contained, however MERS grew to become endemic in the Middle East and brought about a secondary main outbreak in South Korea. In each outbreaks, the excessive mortality and absence of tremendous treatments led to the use of convalescent serum. The biggest learn about concerned the remedy of eighty sufferers with SARS in Hong Kong (20). Patients dealt with earlier than day 14 had accelerated prognosis described by way of discharge from medical institution earlier than day 22, regular with the concept that in the past administration is greater probably to be high quality (20). In addition, these who have been PCR superb and seronegative for coronavirus at the time of remedy had accelerated prognosis (20). There is additionally some anecdotal records on the use of convalescent serum in critically unwell individuals. Three sufferers with SARS in Taiwan had been dealt with with five hundred mL convalescent serum, ensuing in a discount in serum virus titer, and every survived (21). Three sufferers with MERS, South Korea had been dispense with with convalescent serum, however only two of the recipients had neutralizing antibody in their serum (22). The latter learn about highlights a project in the use of convalescent sera, namely, that some who get better from viral sickness may additionally now not have excessive titers of neutralizing antibody (23). Consistent with this point, an evaluation of ninety nine samples of convalescent sera from sufferers with SARS confirmed that 87 had neutralizing antibody, with a geo- metric imply titer of 1:61 (3). This suggests that antibody declines with time and/or that few sufferers make high-titer responses. It is additionally viable that non-neutralizing antibodies are produced that make a contribution to safety and recovery, as described for different viral illnesses (24–26). There are reviews that convalescent serum used to be used for remedy of sufferers with COVID-19 in China at some stage in the present day outbreak (27). Although few important points are reachable from the epidemic in China and posted research concerned small numbers of patients, the handy data suggests that convalescent serum administration decreased viral load and used to be safe.

Risks and benefits

COVID-19 improving sera can be used for both prophylaxis of contamination therapy of disease. In a prophylactic mode, the advantage of convalescent serum administration is that it can forestall contamination and subsequent ailment in these who are at excessive danger for disease, such as prone humans with underlying clinical conditions, fitness care providers, and these with publicity to demonstrated instances of COVID-19. Non-resistant antibody administration to forestall disarray is already used in medical practice. For example, sufferers uncovered to hepatitis B and rabies viruses are handled with hepatitis B immune globulin (HBIG) and human rabies immune globulin (HRIG), respectively. In addition, passive antibody is used for the prevention of extreme respiratory syncytial virus (RSV) disorder in high-risk infants. Until recently, a polyclonal hyperimmune globulin (RSV-IG) organized from samples of donors with excessive serum titers of RSV neutralizing antibody used to be used, after all these preparations have now been changed via palivizumab, a humanized murine mAb. Used therapeutically, convalescent serum would be administered to these with medical ailment in an effort to limit their signs and mortality. The efficacy of these tactics can't be inferred besides carrying out a managed medical trial. Based on the historic ride with antibody administration, it can be predicted that antibody administration would be greater positive in stopping sickness than in the remedy of set up ailment (12).

Risks of passive administration of recovered sera fall into two categories, recognized and theoretical. Known dangers are these related with switch of blood substances, which consist of accidental contamination with every other infectious ailment agent and reactions to serum constituents, which includes immunological reactions such as serum sickness. With cutting-edge blood banking methods that display for blood-borne pathogens and in shape the blood kind of donors and recipients, the dangers of inadvertently transferring recognised infectious retailers or triggering transfusion reactions are low. However, convalescent sera used in a therapeutic mode would possibly be administered to people with pulmonary disease, in whom plasma infusion includes some chance for transfusion- associated acute lung damage (TRALI) (28), and this need to be a consideration in the risk-benefit assessment. The theoretical hazard includes the phenomenon of antibody- established enhancement of contamination (ADE). ADE can appear in a number of viral ailments and entails an enhancement of ailment in the presence of sure antibodies. For coronaviruses, various mechanisms for ADE have been described, and there is the theoretical problem that antibodies to one kind of coronavirus may want to beautify contamination to any other viral stress (29). It may additionally be viable to predict the chance of ADE of SARS-CoV-2 experimentally, as pro- posed for MERS (29). Since the proposed use of convalescent sera in the COVID-19 epidemic would depend on preparations with excessive titers of neutralizing antibody in opposition to the equal virus, SARS2-CoV-2, ADE may additionally be unlikely. The handy proof from the use of convalescent sera in sufferers with SARS1 and MERS (30), and anecdotal proof from its use in 245 sufferers with COVID-19 (27), advise it is

safe. Nevertheless, in convalescent serum trials, warning and vigilance to become aware of any proof of more suitable infection will be required.

Another theoretical chance is that anti- physique administration to these uncovered to SARS-CoV-2 might also forestall disorder in a manner that attenuates the immune response, leaving such humans prone to subsequent reinfection. Passive antibody administration earlier than vaccination with respiratory syncytial virus used to be suggested to attenuate humoral however now not mobile immunity (31). This subject ought to be investigated as section of a medical trial by using measuring immune responses in these uncovered and handled with convalescent sera to forestall disease. If the threat proved real, these people should be vaccinated in opposition to COVID-19 when a vaccine turns into available.

Given that historic and present day anecdotal information on use of convalescent serum propose it is protected in coronavirus infection, the excessive mortality of COVID-19, in particular in aged and prone persons, suggests that the advantages of its use in these at excessive danger for or with early disorder outweigh the risks. However, for all cases the place convalescent serum administration is considered, a risk-benefit evaluation should be performed to verify man or woman variables. These issues had been invoked currently with the choice to use mAbs in the cure of Ebola virus ailment (32).

Deployment and proposed use

To set up convalescent serum administration for COVID-19 the following six prerequisites should be met: (i) availability of a populace of donors who have recovered from the ailment and can donate convalescent serum; (ii) blood banking services to manner the serum donations; (iii) availability of assays, inclusive of serological assays, to discover SARS-CoV-2 in serum and virological assays to measure viral neutralization;

(iv) virology laboratory aid to function these assays; (v) prophylaxis and therapeutic protocols, which ought to ideally consist of randomized scientific trials to investigate the efficacy of any intervention and measure immune responses; and (vi) regulatory compliance, such as institutional overview board approval, which might also range relying on location. Ideally, the use of convalescent serum would contain a couple of centers, observe randomized manage protocols, and have a single core as a governing body. Each of these stipulations need to be on hand in developed areas affected by means of COVID-19. At least one pharmaceutical company, Takeda, is gearing up to generate antibody preparations in opposition to SARS2- CoV-2 from COVID-19 convalescent sera (33). Producing fairly purified preparations containing a excessive titer of neutralizing antibodies towards SARS2-CoV-2 is preferable to convalescent sera given that these are safer and have greater activity. Unfortunately, such preparations will no longer be reachable for many months, whereas domestically produced convalescent sera may want to be accessible a whole lot sooner. We expect that as soon as the indispensable regulatory permissions are in place, folks who get better from COVID-19 can be approached to donate

blood for serum practise or antibody isolation thru apheresis. Recovery from COVID-19 will be assessed clinically, and such people have to be proven to free of SARS-CoV-2, together with in their blood by way of splendid viral nucleic acid screening. Donated blood merchandise will be screened for infectious retailers in accordance to cutting-edge blood banking practices, and person sera will be studied for precise antibody content material and neutralizing recreation to SARS-CoV-2. Depending on the volumes wished and the neutralizing pastime of donated convalescent sera, these should be pooled or used individually, and preparations for scientific use would be handled for pathogen attenuation. At this time, we do no longer recognize what an positive neutralizing titer would be in a inclined man or woman given passive antibody remedy for prophylaxis, and deciding this parameter would be phase of the learn about design. Similarly, we do no longer be aware of what doses would be tremendous therapeutically. We do recognize that when convalescent serum used to be used to forestall measles or mumps the quantities used have been in the order of 10–40 cc (10, 11). In contrast, when convalescent serum was once used to deal with extreme sickness in troopers with 1918 influenza, the quantities given had been in the heaps of milliliters (34). These older research claimed efficacy even although convalescent serum used to be given besides any understanding of neutralizing titers. Those experiences recommend that even small quantities of antibody can also stop and/or deal with infection. Hence, we can assume that positive prophylactic doses would be a great deal smaller than therapeutic doses. This makes sense, when you consider that the infecting inoculum is probable to be tons smaller than the viral burden for the duration of extreme disease.

COVID-19 convalescent sera ought to be used to deal with people with early signs and forestall ailment in these exposed. Today, nurses, physicians, and first responders uncovered to acknowledged instances of COVID-19, some of whom have developed disease, are being quarantined, which threatens to cave in the fitness care system. It is predicted that convalescent serum will forestall SARS-CoV-2 contamination in these to whom it is administered. If this is established, folks who get hold of convalescent sera may additionally be capable to keep away from a duration of quarantine. This should enable them to proceed their crucial characteristic as fitness care providers. Convalescent sera ought to additionally be used to forestall ailment amongst household contributors caring for COVID-19 sufferers at home. Clearly, the use of convalescent serum would be a stopgap measure that should be used in the midst of the contemporary epidemic. However, even neighborhood deployment will entail significant coordination between extraordinary entities, such as infectious ailment specialists, hematologists, blood banking specialists, and medical institution administrators. Hence, as we are in the midst of a global pandemic, we propose that establishments think about the emergency use of convalescent sera and commence preparations as quickly as possible. Time is of the essence.

Reference:

1. Casadevall A, Scharff MD. Return to the past: the case for antibody-based therapies in infectious diseases. *Clin Infect Dis*. 1995;21(1):150–161.

2. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. *Nat Rev Microbiol.* 2004;2(9):695–703.
3. Zhang JS, et al. A serological survey on neutralizing antibody titer of SARS convalescent sera. *J Med Virol.* 2005;77(2):147–150.
4. Beigel JH, et al. Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomal cattle: a phase 1 randomised, double-blind, single-dose-escalation study. *Lancet Infect Dis.* 2018;18(4):410–418.
5. Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. *J Infect Dis.* 1995;171(6):1387–1398.
6. Casadevall A, Pirofski LA. Antibody-mediated regulation of cellular immunity and the inflammatory response. *Trends Immunol.* 2003;24(9):474–478.
7. Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. *Antimicrob Agents Chemother.* 1994; 38(8):1695–1702.
8. Park WH. Therapeutic use of antipoliomyelitis serum in paralytic cases of poliomyelitis. *JAMA.* 1932;99:1050–1053.
9. Park WH, Freeman RG. The prophylactic use of measles convalescent serum. *JAMA.* 1926;87(8):556–558.
10. Gallagher JR. Use of convalescent measles serum to control measles in a preparatory school. *Am J Public Health Nations Health.* 1935;25(5):595–598.
11. Rambar AC. Mumps; use of convalescent serum in the treatment and prophylaxis of orchitis. *Am J Dis Child.* 1946;71:1–13.
12. Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. Hark back: passive immunotherapy for influenza and other serious infections. *Crit Care Med.* 2010;38(4 suppl):e66–e73.
13. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? *Ann Intern Med.* 2006;145(8):599–609.
14. Hung IF, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. *Clin Infect Dis.* 2011;52(4):447–456.

15. Sahr F, et al. Evaluation of convalescent whole blood for treating Ebola virus disease in Freetown, Sierra Leone. *J Infect.* 2017;74(3):302–309.
16. Kraft CS, et al. The Use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. *Clin Infect Dis.* 2015;61(4):496–502.
17. Kong LK, Zhou BP. Successful treatment of avian influenza with convalescent plasma. *Hong Kong Med J.* 2006;12(6):489.
18. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. *N Engl J Med.* 2007;357(14):1450–1451.
19. Wu XX, Gao HN, Wu HB, Peng XM, Ou HL, Li LJ. Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma. *Int J Infect Dis.* 2015;41:3–5.
20. Cheng Y, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. *Eur J Clin Microbiol Infect Dis.* 2005;24(1):44–46.
21. Yeh KM, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. *J Antimicrob Chemother.* 2005;56(5):919–922.
22. Ko JH, et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. *Antivir Ther (Lond).* 2018;23(7):617–622.
23. Arabi YM, et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. *Emerging Infect Dis.* 2016;22(9):1554–1561.
24. van Erp EA, Luytjes W, Ferwerda G, van Kasteren PB. Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease. *Front Immunol.* 2019;10:548.
25. Jenks JA, Goodwin ML, Permar SR. The roles of host and viral antibody fc receptors in herpes simplex virus (HSV) and human cytomegalovirus (HCMV) infections and immunity. *Front Immunol.* 2019;10:2110.
26. Gunn BM, et al. A role for Fc function in therapeutic monoclonal antibody-mediated protection against ebola virus. *Cell Host Microbe.* 2018;24(2):221–233.e5.
27. China puts 245 COVID-19 patients on convalescent plasma therapy. News release. Xinhua. February 28, 2020. Accessed March 10, 2020. http://www.xinhuanet.com/english/2020-02/28/c_138828177.htm.
28. Gajic O, et al. Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. *Am J Respir Crit Care Med.* 2007;176(9):886–891.

29. Wan Y, et al. Molecular mechanism for anti- body-dependent enhancement of coronavirus entry. *J Virol.* 2020;94(5):e02015-19.
30. Mair-Jenkins J, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. *J Infect Dis.* 2015;211(1):80–90.
31. Crowe JE, Firestone CY, Murphy BR. Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. *J Immunol.* 2001;167(7):3910–3918.
32. Mulangu S, et al. A randomized, controlled trial of Ebola virus disease therapeutics. *N Engl J Med.* 2019;381(24):2293–2303.
33. Hopkins JS. Drugmaker Takeda Is Working on Coronavirus Drug. *Wall Street Journal.* <https://www.wsj.com/articles/drugmaker-takeda-is-working-on-coronavirus-drug-11583301660>. Published March 4, 2020. Accessed March 10, 2020.
34. McGuire LW, Redden WR. The use of convalescent human serum in influenza pneumonia-a preliminary report. *Am J Public Health (N Y).* 1918;8(10):741–744.